Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2018

View Archived Issues

Arrevus receives NIAID grant to support research using ARV-1502

Japanese authorities grant Sakigake designation to CLBS-12

Sakigake designation awarded to tafamidis meglumine

Novel HBsAg secretion inhibitors synthesized at Novartis

NOTCH and MAPK signaling linked to worse colorectal cancer survival

Preliminary phase I pharmacokinetic data reported for AZD-8186

Mylan to introduce new triple combo once-daily HIV treatment in U.S.

Incyte patents novel MAP4K1 inhibitors

Nabriva Therapeutics and Roivant Sciences enter lefamulin license agreement

New mu-opioid receptor agonists identified at Mebias Discovery

GlaxoSmithKline presents novel viral 3C and 3CL protease inhibitors

The University of Saskatchewan divulges alpha-synuclein aggregation inhibitors

FDA grants orphan drug designation to CYP-001

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

First patient enrolled in phase IIb trial of AmnioFix Injectable for the treatment of OA of the knee

Vifor Pharma grants Zeria license to develop and market Veltassa in Japan

Abide Therapeutics grants Celgene worldwide license for ABX-1772

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

Lanadelumab submissions in E.U. and Canada accepted for review

Urovant initiates phase III trial of vibegron in overactive bladder

Balixafortide/eribulin combination shows antitumor activity in metastatic breast cancer patients

Curadim licenses rights to Ube's LPA1 selective antagonist

MediciNova announces plans to study MN-166 for chemotherapy-induced peripheral neuropathy

pSivida announces acquisition of Icon Bioscience

Kazia Therapeutics initiates phase II trial of GDC-0084

Five Prime initiates phase I study of first-in-class B7-H4 antibody FPA-150

METTL3 linked to hepatocellular carcinogenesis

Prometic Life Sciences offers new data from phase II study of PBI-4050 in Alstrom syndrome

Janssen files for approval of apalutamide in Japan

Takeda considers making offer for Shire

Zeria Pharmaceutical applies for approval of Z-213 in Japan

Redx suspends enrollment in phase I/IIa study of RXC-004

C4X licenses orexin-1 receptor antagonist C4X-3256 to Indivior

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...